Single Psilocybin Dose Provides Rapid Relief From Depression, Small Clinical Trial Finds

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

MONDAY, May 18, 2026 — Just a single dose of psilocybin can provide rapid relief from depression, a new small-scale clinical trial has shown.

Within a week, people treated with one psilocybin dose had four times the decrease in their depression symptoms compared to a control group given the vitamin niacin, researchers reported May 15 in JAMA Network Open.

And after six weeks, half (nearly 53%) of the psilocybin patients had no depression at all, compared with about 6% in the control group, the study found.

"Our results suggest that psilocybin can provide rapid, clinically meaningful improvement in depression and may serve as an alternative to standard treatment when fast symptom reduction is important,” said lead researcher Dr. Hampus Yngwe, a doctoral student and consultant psychiatrist at the Karolinska Institute in Sweden.

"However, the long-term effects are uncertain,” Yngwe said in a news release. “Repeated treatments may be needed to prevent relapse. This needs to be investigated in larger studies.”

Previous studies have found that psilocybin, found in “magic mushrooms,” might have an antidepressant effect in people.

Current antidepressant drugs don’t work for all patients, and their effects can take several weeks to kick in, researchers noted.

For the new study, researchers recruited 35 people ages 20 to 65 who had at least a 22 score on the 60-point Montgomery-Asberg Depression Rating Scale (MADRS). A score of 20 to 34 points indicates moderate depression and 35 to 60 points severe depression.

Half of the patients were randomly assigned to take a single 25 milligram dose of psilocybin. The other half took niacin, a vitamin that can cause noticeable physical reactions like flushing.

All participants were asked to lie down on the day of treatment and focus inwardly while wearing an eye mask and listening to music.

Eight days after treatment, the psilocybin patients had an average decrease of 9.7 points in their MADRS score, compared to 2.4 for the placebo group.

The effect persisted for at least six weeks, with half the psilocybin patients in remission from depression at that point.

After a year, the same number of psilocybin patients were still in remission, but by then as many of those who had taken niacin also had recovered, researchers said.

Researchers noted that two of the participants who took psilocybin reported severe and persistent anxiety that needed medical attention. Psychotherapy support was available to all participants during the treatment day.

“It is important to emphasize that the treatment is not risk-free and that some patients may need extra support,” senior researcher Dr. Johan Lundberg said in a news release. Lundberg is a professor of clinical neuroscience at the Karolinska Institute.

One drawback – almost all the participants could tell whether they’d taken psilocybin or niacin, which might have influenced their outcomes, researchers noted.

Researchers next plan to analyze brain scans, as well as blood and spinal fluid samples, that were taken before and after people received their dose.

“Research suggests that the interaction between parts of the brain is impaired in depression and that this may be linked to changes in the connections between nerve cells, known as synapses,” Yngwe concluded. “In preclinical studies, psychedelics have been shown to stimulate synaptic growth. We therefore want to investigate whether psilocybin alters synaptic density in the brain.”

Sources

  • Karolinska Institute, news release, May 15, 2026
  • JAMA Network Open, May 15, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-05-18 22:21

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords